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Abstract
Hepatocellular carcinoma (HCC) is an aggressive tumor
that often occurs in the setting of chronic liver disease.
Many patients do not initially manifest any symptoms of
HCC and present late when cure with surgical resection
or transplantation is no longer possible. For this reason,
patients at high risk for developing HCC are subjected
to frequent screening processes. The surgical management of HCC is complex and requires an inter-disciplinary approach. Hepatic resection is the treatment of
choice for HCC in patients without cirrhosis and is indicated in some patients with early cirrhosis (Child-Pugh
A). Liver transplantation has emerged in the past decade as the standard of care for patients with cirrhosis
and HCC meeting Milan criteria and in select patients
with HCC beyond Milan criteria. Loco-regional therapy
with transarterial chemoembolization, transarterial embolization, radiofrequency ablation and other similar local treatments can be used as neo-adjuvant therapy to
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downstage HCC to within Milan criteria or as a bridge
to transplantation in patients on transplant wait list.
© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Hepatocellular carcinoma; Liver transplantation; Liver resection; Transarterial chemoembolization;
Radiofrequency ablation
Core tip: This is a review article on the current strategies for the management of hepatocellular carcinoma
in North America. This article covers the evolution of
techniques and provides comparison between different
modalities discussed.
Khan AS, Fowler KJ, Chapman WC. Current surgical treatment
strategies for hepatocellular carcinoma in North America. World J
Gastroenterol 2014; 20(41): 15007-15017 Available from: URL:
http://www.wjgnet.com/1007-9327/full/v20/i41/15007.htm DOI:
http://dx.doi.org/10.3748/wjg.v20.i41.15007

INTRODUCTION
Hepatocellular carcinoma (HCC) is an aggressive tumor
that often occurs in the setting of chronic liver disease
and cirrhosis. It is the fifth most frequently diagnosed
cancer worldwide and the third leading cause of cancer
death[1]. Traditionally the rates of HCC in North America
have been low compared to Asian and sub-Saharan African countries (15 per 100000 in Asia and Africa compared to less than 3 per 100000 in North America)[1,2].
However, the last two decades have seen a significant
increase in the incidence of HCC in the United States
where the risk of HCC is linked significantly to chronic
viral hepatitis (hepatitis C virus and hepatitis B virus),
alcohol consumption and nonalcoholic fatty liver disease[3-7]. The presence of these risk factors predisposes
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A

Table 1 American liver tumor study group modified tumornode-metastasis staging classification for hepatocellular
carcinoma
Tumor
classification
T0, N0, M0
T1
T2
T3
T4a
T4b

N1
M1

Definition

Stage

Criteria

No tumor found
1 nodule < 2.0 cm
Stage Ⅰ
T1 lesion
1 nodule 2-5 cm, 2 or 3 nodules Stage Ⅱ
T2 lesion
each less than 3 cm
1 nodule > 5 cm, 2 or 3
Stage Ⅲ
T3 lesion
nodules, at least 1 > 3 cm
≥ 4 nodules, any size
Stage Ⅳa1
T4a
T2, T3 or T4a plus gross
Stage Ⅳa2
T4b
intrahepatic, portal or hepatic
vein involvement as indicated
by CT, MRI or US
Regional (porta hepatis) node Stage Ⅳb Any N1 or
involvement
M1
Metastatic disease including
extrahepatic portal or hepatic
vein involvement

Arterial phase

B

HCC: Hepatocellular carcinoma; CT: Computed tomography; MRI:
Magnetic resonance imaging; US: Ultrasound; TNM: Tumor node
metastasis.
Portal venous phase

patients to the development of cirrhosis and HCC by the
common pathway of inducing chronic inflammation of
the liver, which acts as the backdrop for genetic mutations to amass and drive cells towards malignancy[8]. The
American Association for the Study of Liver Diseases
(AASLD), Asian Pacific Association for the Study of the
Liver and the European Association for the Study of the
Liver, all have well defined guidelines for diagnosis and
management of HCC which are fairly similar to each
other other than some minor differences based on disease etiology and epidemiology[9-11].

DIAGNOSIS
Patients who develop HCC often have no symptoms
other than those related to chronic liver disease. Therefore
it is not unusual for HCC to be diagnosed in advanced
stages (Table 1) when cure with surgical resection or transplantation is no longer possible. For this reason, patients
at high risk for developing HCC are subjected to regular
screening with ultrasound and tumor markers in accordance with the updated guidelines of AASLD[11]. Patients
with high index of suspicion for HCC on screening then
undergo additional non-invasive testing with either contrast enhanced computed tomography (CT) or gadolinium
enhanced magnetic resonance imaging (Figure 1). These
imaging modalities can reliably establish the diagnosis of
HCC in most patients without the need for biopsy and
also provide information on the size and number of lesions, relationship with vascular structures and evidence
of extra-hepatic spread. Additionally, chest CTs and bone
scans are routinely used to assess for metastatic disease.
Traditionally Positron emission tomography scan has had
a limited role in HCC staging as HCC has shown variable
degrees of fluorodeoxyglucose (FDG) uptake, which lim-
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Figure 1 Magnetic resonance imaging of hepatocellular carcinoma in
segment 8. Arterial enhancement (A, arrow), washout and pseudocapsule (B,
arrow).

its sensitivity[12]. However recent application of PET using
11
C-Acetate and 18F-FDG has shown it to be an effective
HCC staging modality especially in patients with high alpha fetoprotein levels, primary lesions with high SUV max
values and for lesions beyond Milan criteria[13,14].
Cirrhosis of the liver underlies HCC in almost 90%
of cases and the extent of underlying cirrhosis plays a
vital role in determining treatment options and overall
outcomes[7]. Traditionally, surgical resection has been the
only option for cure but more often than not, the extent
of HCC or the degree of underlying parenchymal disease
precludes surgical resection. In the last two decades, liver
transplantation has emerged as an effective and viable
option for treatment of HCC in select patients who otherwise would not have been candidates for surgical resection[7]. Other therapies such as radiofrequency ablation
(RFA), microwave ablation, transarterial embolization
(TAE) and transarterial chemoembolization (TACE) can
be used alone or in combination with surgical resection
or transplantation to effectively treat selected patients
with HCC. Tables 2 and 3 provide a brief summary of
the indications, advantages and disadvantages of the
commonly used treatment options for management of
HCC in North America today.

HEPATIC RESECTION
Introduction
Hepatic resection has been the standard treatment for
HCC in selected patients with limited disease and early
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Table 2 Current indications of commonly used treatment options for hepatocellular carcinoma
Current indications
Hepatic resection

OLT

Non resectional
ablative therapies (RFA,
microwave, TACE, TAE,
HIFU etc.)

Treatment of choice in patients with resectable disease and absence of cirrhosis
Indicated in selected patients with limited disease and early cirrhosis (Child-Pugh A)
Limited role as a bridge to OLT
Standard therapy for patients with HCC and Cirrhosis within Milan criteria
OLT may be indicated in select patients with tumors outside Milan criteria but within UCSF criteria
Indicated in select patients with stage III and IV HCC downstaged to within Milan criteria with use of neo-adjuvant therapy
Indicated as primary therapy only in patients with HCC who are not candidates for curative resection or OLT
Increasingly used alone or in combination as bridging therapy in patients awaiting OLT or to downstage stage advanced
stage disease to within Milan criteria
Established role in palliative treatment of HCC (not discussed in this paper)

HCC: Hepatocellular carcinoma; OLT: Orthotopic liver transplant; UCSF: University of California San Francisco.

Table 3 Overview of the common modalities used in the treatment of hepatocellular carcinoma
Treatment modality
Hepatic resection

OLT

TACE/TAE

RFA

Advantages

Disadvantages

Readily accessible
No waiting period
5 yr survival of > 50% in carefully selected patients
Peri-operative mortality < 5%
Not limited by tumor size
Low rate of recurrence in carefully selected patients
Post transplant survival rates similar to patients with OLT
for all other causes
Indicated for treatment in patients not candidates for
resection or OLT
Effective role as bridge for transplantation
Established role in downstaging HCC to make patients OLT
eligible
Evidence of survival benefit after OLT when used as
neo-adjuvant therapy in select patients
Relatively low morbidity
Highly effective for HCC ≤ 3 cm

Not indicated for patients with advanced cirrhosis
High recurrence rates (> 50% at 5 yr)
Risk of post operative haptic failure
Does not address risk of cancer in residual liver
Restricted by size and number of lesions
Risk of dropout while on wait list (38% drop out rate after 12
mo)
Low curative potential when used alone with high recurrence
rates
Efficacy decreased for large sized tumors
Does not address risk of cancer in residual liver

Decreased effectiveness in HCC ≥ 4 cm with high recurrence
rates
Effective bridge for OLT by decreasing drop out rate on wait May be limited by proximity of HCC to vascular pedicels
list
Established role in downstaging HCC to make patients OLT Does not address risk of cancer in residual liver
eligible
Relatively low morbidity and mortality

HCC: Hepatocellular carcinoma; OLT: Orthotopic liver transplantation; TACE: Transarterial chemoembolization; TAE: Transarterial embolization; RFA:
Radiofrequency ablation.

cirrhosis (Child-Pugh A)[15,16]. With advances in surgical
technique and better understanding of disease pathophysiology, resection for HCC can now safely be performed
in most major centers with a peri-operative mortality rate
of less than 5%[15-17]. Moreover, five-year survival rates
of over 50% have been reported in carefully selected
patients with small, solitary tumors and well-preserved
hepatic function, which supports the therapeutic role of
resection in the treatment algorithm[17-19].
Advantages and disadvantages
In theory, hepatic resection for HCC has several advantages when compared to other therapeutic modalities
such as liver transplantation and thermal ablation. It is
more readily applicable, does not have an associated waiting time, and is not restricted by tumor size or proximity
to hepatic veins and portal pedicles[15-17,20]. The effective-
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ness of the surgery can be gauged early by tumor free
margins on pathologic analysis and the ability to maintain
an adequately functioning liver remnant. However, not
every patient with localized HCC is a candidate for resection. Moreover resection does not address the remnant
liver, which remains at risk for developing cancer[15,17,21].
Prognostic factors
Currently, surgery is preferred in patients with HCC
without any underlying liver disease and in select patients
with early cirrhosis (Child-Pugh A)[16,17]. The extent of
underlying liver dysfunction has repeatedly been shown
to be an important determinant of overall outcome with
peri-operative morbidity and mortality being directly proportional to the degree of cirrhosis[18,19]. Parenchymal disease dictates the amount of resection that can be safely
done without risking post-operative hepatic failure due to
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a small liver remnant[18,19,21]. Cirrhosis also increases the
risk of peri-operative bleeding and the need for blood
transfusions, factors shown to be independently associated with increased morbidity and mortality[15,20].
The size of HCC and total number of lesions are
important determinants of outcome after hepatectomy[15,18,22]. Zhou et al[16], in their review of 1000 patients
undergoing hepatectomy for HCC observed that patients
with tumors greater than 5 cm had a significantly lower
survival when compared to those with smaller lesions
(37% vs 63%). Similarly, Fong et al[17] reported five-year
survival of 57% for patients with resected lesions less
than 5 cm and only 32% for patients with tumors greater
than 10 cm. However, a more recent study from the same
group showed that in carefully selected patients with large
tumors (> 10 cm), resection can achieve similar overall
survival and recurrence-free survival as patients with
smaller tumors[23]. Multi-focal or multi-nodular HCC is a
poor prognostic sign and hepatectomy in these patients is
associated with high recurrence rates (> 90%) and poor
survival (< 30%)[18,19,24].
Vascular invasion has repeatedly been shown to be
one of the strongest negative prognosticators in patients
undergoing hepatectomy for HCC[20,25,26]. Lang demonstrated 1, 3 and 5-year survival rates of 57%, 16% and 6%
respectively in patients undergoing resection for HCC
with vascular invasion compared to 93%, 75% and 53%
in patients without vascular invasion[20]. Five-year survival
after hepatectomy in patients with vascular invasion may
be increased to over 20% in the absence of underlying
liver fibrosis[26].
There have been many studies looking at the impact
of resection margin on recurrence and survival after
HCC resection. Though there is universal consensus that
an R0 resection is better than a resection with positive
margins, there are no clear-cut guidelines on the minimum negative margin required[20]. A recent randomized
trial compared resection outcomes for solitary HCC
by randomizing 169 patients to undergo hepatic resection with either narrow (1 cm) or wide (2 cm) resection
margins. Both groups were matched for tumor size. The
authors reported significantly improved survival and reduced tumor recurrence in the wide margin group[27]. A
more recent meta-analysis did not show a significant difference in outcomes after hepatectomy for HCC between
resection margins less than 1 cm and margins equal to or
greater than 1 cm[28].
Some additional factors associated with reduced survival after hepatectomy for HCC include presence of
satellite lesions or intra-hepatic metastases, poor tumor
differentiation, elevated alkaline phosphatase levels and
high serum alpha-fetoprotein levels[18,19,22,25].
There have been several reports recently on laparoscopic resections for HCC. Most of these reflect highly
selected patients with isolated and easily accessible
disease, which makes direct comparison with open resection difficult[29,30]. A recent multicenter cohort study
from France reviewed results of laparoscopic resection
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for hepatocellular carcinoma in 351 patients. Eighty five
percent of the patients had underlying liver disease and
11% had major hepatectomy. They reported 30-d postoperative mortality of 2%. Ninety two percent had R0
resection and reported overall 1, 3 and 5-year survivals of
90.3%, 70.1% and 65.9% respectively. These results compare favorably with the reported outcomes after open
resection[29].
HCC in early cirrhosis: Resection vs OLT
The use of resection for patients with early cirrhosis
(Child-Pugh A) and HCC that falls within the Milan criteria is a controversial decision at most US centers as these
patients may instead be candidates for transplantation.
Studies comparing the two modalities show comparable
overall adjusted survival. The higher recurrence rate after
resection is balanced by the risk of dropout due to disease
progression in patients awaiting OLT[21,31,32]. At most centers this decision is made on a case-to-case basis after discussion in multi-disciplinary meetings and tumor boards.
Hepatic resection as a bridge to orthotopic liver
transplantation
Several groups have studied surgical resection as a bridge
to transplantation (this will be discussed more in the section on transplantation). One concerning trend noted
in many of these studies is the high number of patients
(> 30%) with recurrent HCC after liver resection that
is beyond the Milan criteria, making them ineligible for
transplantation at most centers[33-35]. However, survival
after salvage liver transplantation for patients with recurrences within Milan Criteria has shown to be comparable
to survival after primary orthotopic liver transplantation
(OLT) in a recent meta-analysis of 1508 patients, making
it a reasonable option in carefully selected patients[36].

LIVER TRANSPLANT
Introduction
Liver transplantation is now considered standard therapy
for selected patients with early stage HCC and liver cirrhosis[12,21]. Initial experience with liver transplantation for
HCC resulted in dismal outcomes. High recurrence rates
(65%-75%) and poor survival seen in these early reports
considerably diminished the interest in liver replacement
for hepatic malignancy and a moratorium was placed on
liver transplantation for HCC outside of clinical trials in
1989[37-39].
Milan criteria for transplantation for HCC
Interest in liver transplantation for HCC was renewed in
1996, when Mazzaferro and his group showed survival
after liver transplantation in patients with cirrhosis and
early-stage HCC to be comparable to results after liver
transplantation in patients with benign disease[40]. This
prospective cohort study included 48 cirrhotic patients
who underwent transplantation for HCC with single tumors less than or equal to 5 cm or up to 3 tumors, each 3
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cm or less in diameter. The actuarial 4-year survival was
75%, which was not different from expected survival of
patients with non-malignant indications[40]. This study
formed the basis for the Milan criteria. These results were
validated by several studies and interest in transplantation
as a therapeutic option for patients with early stage HCC
was renewed.
Model for end stage liver disease allocation and
exception points for HCC
Currently in the US, livers are allocated for transplantation using the model for end stage liver disease (MELD)
score, which predicts the three-month mortality of patients awaiting liver transplantation. Realizing that the
MELD system would be of little benefit to patients with
compensated cirrhosis and early stage HCC, UNOS in
2002 adopted the Milan criteria for allocating exception
points to patients with HCC listed for liver transplantation. At the present time, patients with stage 2 HCC (Milan criteria - 1 nodule up to 5 cm or 3 nodules with the
largest one 3 cm or less) can receive 22 MELD exception
points which decreases the wait time for receiving a liver
to between 6 mo and 12 mo at most transplant centers in
North America[37,41]. Currently patients with cirrhosis and
HCC beyond Milan criteria do not qualify for MELD
exception points despite otherwise meeting criteria for
OLT. These patients can be listed for OLT based on their
original MELD score, however the likelihood of timely
OLT before HCC progression is small without allocation
of priority points. Transplant centers can selectively petition regional review boards for MELD exception points
in HCC patients exceeding Milan Criteria or in those who
have been effectively down-staged and are considered on
a case to case basis[21,37].
Results for survival and disease free interval after liver
transplantation for patients have significantly improved
after implementation of the Milan criteria. In a review
of their 20-year experience with liver transplantation
for HCC, Onaca et al[42] reported an increase in five year
patient survival from 28.6% in 1987-1992 and 42.3% in
1992-1997 to 76% after 1997, when Milan criteria was
implemented. Similar observations were made in several
other studies and as a result, the number of liver transplants performed annually in the US for HCC increased
almost three fold between 2002 and 2006[21]. In most recent series, the overall five and ten year survival following
transplantation for HCC is comparable to the five and
ten-year survival rates for all causes[12,21,37].
Extended criteria for transplantation for HCC
In recent years there has been a push by many transplant
centers for expanding the Milan criteria. It is felt that the
Milan criteria is too restrictive and limits the use of transplantation to patients with very early stage HCC. Several
groups have challenged these restrictions by either expanding the inclusion criteria or by using liver directed
therapy to downstage patients with advanced disease to
“within Milan criteria”. The most notable contribution in
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this regard came from the University of California San
Francisco (UCSF) group who proposed expanding the
Milan criteria to include single lesion ≤ 6.5 cm or up to 3
lesions, the largest ≤ 4.5 cm and total tumor diameter ≤
8 cm without gross vascular invasion[43]. The group based
their recommendations on the observation that the explant pathology often showed under-staging of HCC by
preoperative cross sectional imaging and that this did not
appear to impact the overall outcome. The initial paper
reviewed 168 HCC patients that under underwent OLT
and reported a 5-year recurrence free survival of 90%
for patients with tumors within Milan vs 94% for patients
with tumors that exceeded Milan but were within the
UCSF criteria[43]. A follow-up study from the same group
again evaluated the expanded criteria in 467 patients and
showed that patients meeting Milan criteria had similar
5-year post transplant survival to patients meeting UCSF
criteria by preoperative imaging (79% vs 64%) and explant pathology (86% vs 71%)[44]. Since then several other
centers have reported similar results in patients exceeding
Milan criteria[45-49].
Beyond UCSF?
There is little enthusiasm for extending liver transplantation beyond the UCSF criteria as survival has shown to
be significantly reduced once the size exceeds UCSF criteria[44,45]. This has led to a renewed interest in using neoadjuvant techniques for downsizing prohibitively large
HCC’s in patients who may otherwise be amenable for
transplantation.
Down-staging advanced stage HCC
Selected patients with advanced stage HCC (stage Ⅲ/Ⅳ)
who are not candidates for transplantation can be downstaged with the use of neo-adjuvant loco-regional therapy
to “within Milan criteria” so that they can become transplant eligible. This practice has been adopted by an increasing number of transplant centers in North America
with promising results. A recent report from Washington
University in St Louis demonstrated the feasibility of this
approach by successfully down-staging 18 of 76 patients
(23.7%) with stage Ⅲ/Ⅳ disease to ‘‘within the Milan
criteria’’ using TACE. Seventeen of these patients went
on to receive OLT at a median of 58 ± 3.5 mo after first
TACE with an actuarial overall 5-year survival rate of
93.8%. This compared favorably to a 5-year survival rete
of 66% in patients with stage Ⅱ disease that were chemoembolized and transplanted[50]. Similar results were reported by the UCSF group who utilized TACE for tumors exceeding Milan but within UCSF criteria. Forty-three of 61
patients (70.5%) were successfully down-staged, of which
35 went on to receive OLT with reported 1 and 4-year
overall survival retes of 96.2% and 92.1% respectively[51].
The promising results from these two groups suggest
that this strategy may help identify patients with favorable
tumor biology who would carry good prognosis for longterm survival after OLT. Current recommendations call
for an observation period of at least 3-6 mo after down-
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Figure 2 Treatment of hepatocellular carcinoma with transarterial chemoembolization. A, B: Angiographic images demonstrate arterial blush of hepatocellular
carcinoma (HCC) (white arrowhead) with a proper hepatic arterial injection. Coned down view shows tumor blush and stasis in the segmental arteries supplying the
HCC following transarterial chemoembolization (B); C, D: Follow up magnetic resonance imaging 4 wk after treatment shows no residual arterial enhancement in the
treated area (white arrows) compatible with a complete response per modified response evaluation criteria in solid tumors.

staging with TACE before considering transplantation.
The purpose of this observation period is to assess the
biological aggressiveness of the tumor[21].
Pretreatment of patients on transplant list: Bridge to
transplant
An ever-increasing demand for a relatively fixed pool
of deceased donor organs has caused HCC patients to
spend more and more time on the wait list. This carries
a high cumulative probability of dropout due to intrahepatic or extrahepatic tumor progression. Llovet et al[52]
and Yao et al[53] showed this probability to be between
7%-11% at 6 mo and approximately 38% at 12 mo following enrollment for OLT. Consequently, several therapeutic procedures have been proposed as bridging treatments for patients with HCC with the aims of decreasing
waiting list dropout rate, reducing HCC recurrence after
transplantation and improving post-transplant overall
survival[54]. The most commonly used bridging modalities include TACE or TAE, ablation therapy with either
RFA or percutaneous ethanol injection (PEI), and surgical resection. There are no randomized trials establishing
efficacy of these treatments and clinical practices vary
greatly between transplant centers.
TACE/TAE: TACE/TAE has a well-established role
as bridging therapy for patients awaiting OLT. The most
commonly used TACE procedure involves an arterial
infusion of a lipiodol emulsion with a chemotherapeutic
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agent (e.g., doxorubicin, mitomycin or cisplatin) followed
by embolization with gelfoam. Follow up cross sectional
imaging is usually done 4-6 wk later to assess for completeness of ablation (Figure 2). If there is evidence of
residual disease, TACE can be repeated[12,54].
Results from most series indicate complete tumor
necrosis rates of 27%-57% in patients with stage Ⅰ and
[50]
Ⅱ disease treated with TACE . There is also evidence
to suggest that the use of TACE as neo-adjuvant therapy
may provide survival benefit after transplantation as well.
Yao et al[55] demonstrated a 5-year post transplant recurrence free survival of 93.8% for patients who received
preoperative loco-regional therapy vs 80.6% in patients
who were not pre-treated. Similarly, a report by Bharat
et al[56] demonstrated a 5-year survival of 83.4% in pretreated patients vs 51.8% in patients who did not receive
any preoperative loco-regional therapy. Interestingly, both
of these studies demonstrated treatment benefit only in
patients with larger sized (T2-T4) tumors. Additionally,
survival was highest in patients with 100% tumor necrosis in explant specimen irrespective of size[56].
RFA: RFA is also being increasingly used as a bridge to
transplantation in HCC patients in North America. Studies have reported complete tumor necrosis in 47%-75%
of patients on explant analysis. Predictably, the rate of
tumor necrosis is highest in tumors less than 3 cm[54].
Mazzaferro et al[57] reported no patient drop-out due to
disease progression after median waiting time of 9.5 mo
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Figure 3 Pretreatment of patients on transplant list (other modalities). A and B: Arterial enhancing hepatocellular carcinoma lesion in segment 5/8 (arrows) that
shows subtle washout and possible pseudocapsule on delayed post-contrast imaging. This tumor was treated successfully using percutaneous microwave ablation; C:
The tip of the microwave ablation probe positioned within the lesion (white dotted circle). Note the presence of a transjugular intrahepatic portosystemic shunt catheter
(white dotted arrow) which helped direct placement of the probe on fluoroscopic images; D, E: Follow up magnetic resonance imaging 4 wk after ablation shows large
ablation cavity covering the region of the previously seen tumor (arrows). There is no residual arterial enhancement suggesting complete tumor necrosis.

in 50 patients undergoing pre-transplant RFA. The 1 and
3-year post transplant survival was reported at 95% and
83% respectively.
Liver resection: The role of liver resection as a bridge
to transplantation is controversial. Approximately 70%
of patients develop recurrent disease after resection and
about one-third of them recur beyond Milan criteria
making them transplant ineligible at most centers[33-35].
However, survival after salvage liver transplantation
for patients with recurrences within Milan Criteria was
shown in a recent meta-analysis to be comparable to survival after primary OLT[36]. Currently in the United States,
patients on OLT waiting list who have already undergone
liver resection for HCC are not awarded MELD score
exception points, which makes it a less attractive option.
Other modalities: PEI is one of the oldest techniques
for local treatment of HCC and it is rarely used as a
bridging treatment for transplantation[54]. Microwave
ablation, high-intensity focused ultrasound (HIFU)
ablation, percutaneous laser ablation, conformal radio
therapy and transarterial radioembolization, are some of
the new and upcoming techniques that may play a role as
a bridge to transplantation in the future either alone or
in combination therapy with other established modalities
(Figure 3). A recent pilot study showed promising results
with use of HIFU ablation as bridging therapy for HCC
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patients on transplant wait list who were not candidates
for TACE or radiofrequency ablation. Patients in the
HIFU group had comparable percentages of tumor necrosis on explant specimen to TACE patients and this
technique was found to be safe even in patients with
advanced cirrhosis (Child-Pugh C). It still remains to be
seen whether these promising initial results will be reproduced in a RCT[58].
Non resectional ablative therapies
Ablative therapies have emerged in the past decade as effective treatment options for select patients with HCC.
RFA and TACE/TAE are the more commonly employed
ablative techniques and work by causing tumor necrosis.
These techniques have shown to be reasonably effective
for small tumors but also have significant limitations[15,57].
Consequently their role for primary treatment of HCC
is limited at the present time for patients with advanced
disease that is not amenable for resection or transplantation or in patients who are at a prohibitively high risk for
major surgery. Additionally, RFA and TACE/TAE are
now increasingly being used as a bridge to transplantation
in an attempt to decrease dropout rate for patients on
transplant waiting list. Recent reports have also supported
the use of loco-regional ablative techniques to downstage
patients with advanced HCC to ‘‘within Milan criteria’’
where they can be listed for OLT[21,50,51,56,59].
Microwave ablation, high intensity focused ultrasound
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and irreversible electroporation are some of the newer
ablative techniques that will likely find a place in the treatment algorithm of HCC alongside RFA and TACE.
We will only discuss RFA under this section as others
have been discussed under the section of bridging for
transplantation.
RFA: RFA has emerged as an effective treatment option
for select patients with HCC limited to the liver and who
do not meet criteria for resectability. RFA has also been
increasingly used along with TACE/TAE as “bridging”
therapy in patients awaiting liver transplantation or to
downsize patients with stage Ⅲ/Ⅳ HCC to Milan criteria for subsequent liver transplantation as discussed
earlier. It is performed percutaneously in the majority of
cases and effectiveness varies greatly with tumor size and
location[21].
RFA involves application of thermal energy to the
lesion using high frequency alternating current. As the
temperature of the tumor tissue rises above 60 degrees
Celsius, cells begin to die, resulting in an area of coagulative necrosis around the RF electrode. It can be used
alone or in combination with TAE/TACE for management of HCC.
The HCC treatment algorithm established by the
AASLD recommends ablative treatment for HCC nodules with a maximal diameter of 3 cm in patients with 3
or fewer tumors and in whom resection is otherwise contraindicated[60]. Chen et al[61] reported their results from
a randomized control trial comparing survival between
surgical resection and ablative therapy in 180 patients
with solitary HCC up to 5 cm in size. They demonstrated
comparable 1 and 4 year survival rates of 95.8%, 67.9%
and 93.3%, 64.0% after ablative therapy and surgery
respectively. The corresponding 1 and 4-year diseasefree survival rates were 85.9%, 46.4% and 86.6%, 51.6%
respectively. Combination therapy with TACE and RFA
been shown to be safe and effective for solitary HCC’s
greater than 5 cm with approximate recurrence free survival times of 17 mo[59,62].
Choi et al[63] reported a 5 year local recurrence rate
and corresponding survival rate of 11.9% and 51.6%
respectively for 101 patients with recurrent HCC after
hepatectomy, who then underwent percutaneous ultrasound guided RFA. In a recent prospective randomized
trial, Peng et al[64] demonstrated that combination therapy
with TACE and RFA was more effective than RFA alone
for treatment of recurrent HCC. This difference was
significant for recurrent tumors greater than 3 cm in size.
It is important to realize that although TACE and RFA
may prolong survival, at this time they are not considered
curative treatment options for HCC. Additionally like
hepatic resection, ablative techniques do not address the
risk of HCC in the remnant cirrhotic liver.

quires an inter-disciplinary approach. Hepatic resection
is the treatment of choice for HCC in patients without
cirrhosis and is indicated in some patients with early
cirrhosis (Child-Pugh A). Effectiveness of surgery is
dependent on ability to achieve negative margins while
maintaining an adequately functioning liver remnant.
Large HCC, multifocal disease, underlying cirrhosis and
vascular invasion by the tumor are some of the major
factors negatively impacting outcome after surgical resection. Liver transplantation is the established standard of
care for patients with cirrhosis and HCC meeting Milan
criteria and in select patients with HCC beyond Milan
but within UCSF criteria. Neo-adjuvant loco-regional
therapy (TACE/TAE, RFA etc.) followed by a period
of observation must be considered for patients beyond
Milan criteria in an attempt do downstage them to meet
Milan criteria. Loco-regional therapies (TACE/TAE and
RFA) can also be used as a bridge to transplantation with
favorable oncologic outcomes and reduced dropout rates
in patients awaiting OLT. The role of hepatic resection as
bridge for transplantation is controversial.
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